Chitapanarux Imjai, Lekawanvijit Suree, Sripan Patumrat, Mahanupab Pongsak, Chakrabandhu Somvilai, Onchan Wimrak, Sittitrai Pichit, Boonlert Donyarat, Klibngern Hanpon, Samuckkeethum Wisarut
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Res Med Sci. 2020 Apr 13;25:34. doi: 10.4103/jrms.JRMS_787_18. eCollection 2020.
Overexpression of excision repair cross-complementing Group 1 (ERCC-1) is related to cisplatin resistance and defective repair of radiation damage. The purpose of this study was to evaluate the clinical significance of excision (ERCC-1) expression in nasopharyngeal cancer (NPC).
We conducted a retrospective review of patients diagnosed with NPC between 2000 and 2013. The archived tissues were analyzed using immunohistochemistry to determine ERCC-1 expression. The ERCC-1 expression level along with other clinical factors and overall survival (OS) were analyzed. Hazard ratio (HR) with a 95% confidence interval was calculated to assess the risk.
The analysis of ERCC-1 expression was available in 262 NPC patients who had medical records at our hospital. Among those patients, 221 (84%) were treated with curative radiotherapy (RT)/concurrent chemoradiotherapy, 22 (7%) were treated with palliative RT alone, and 19 (9%) were given best supportive care. There was no correlation between ERCC-1 expression and stage of cancer or OS. No difference in 5-year OS was found between patients with low ERCC-1 expression and high ERCC-1 expression (38% vs. 36%; = 0.981). The adjusted HR (aHR) of cancer death increased with cancer stage (aHR = 2.93 for advanced Stages III-IV; = 0.001) and age (aHR = 2.11 for age >55; ≤ 0.001). ERCC-1 expression exhibited no prognostic significance in our study (aHR = 1).
In this study, ERCC-1 expression has no statistical significance to be considered a prognostic factor for OS among NPC patients. On the other hand, cancer stage, age, and types of treatment can be prognostic factors in NPC patients.
切除修复交叉互补基因1（ERCC-1）的过表达与顺铂耐药及辐射损伤修复缺陷有关。本研究旨在评估切除修复交叉互补基因1（ERCC-1）在鼻咽癌（NPC）中的表达的临床意义。
我们对2000年至2013年间诊断为鼻咽癌的患者进行了回顾性研究。使用免疫组织化学分析存档组织以确定ERCC-1的表达。分析了ERCC-1表达水平以及其他临床因素和总生存期（OS）。计算了95%置信区间的风险比（HR）以评估风险。
对我院有病历记录的262例鼻咽癌患者进行了ERCC-1表达分析。在这些患者中，221例（84%）接受了根治性放疗（RT）/同步放化疗，22例（7%）仅接受了姑息性放疗，19例（9%）给予了最佳支持治疗。ERCC-1表达与癌症分期或总生存期之间无相关性。低ERCC-1表达患者和高ERCC-1表达患者的5年总生存期无差异（38%对36%；P=0.981）。癌症死亡的调整后风险比（aHR）随癌症分期（III-IV期晚期的aHR=2.93；P=0.001）和年龄（年龄>55岁的aHR=2.11；P≤0.001）增加。在我们的研究中，ERCC-1表达无预后意义（aHR=1）。
在本研究中，ERCC-1表达作为鼻咽癌患者总生存期的预后因素无统计学意义。另一方面，癌症分期、年龄和治疗类型可能是鼻咽癌患者的预后因素。
